newsfilter
← Latest News
GlobeNewswire·

Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Initiated a Phase 1/1b clinical trial for IVX-121, a virus like particle (VLP) vaccine candidate displaying the prefusion stabilized Respiratory Syncytial Virus (RSV) F antigen - - Completed dosing in ongoing Phase 1/2 clinical trial for IVX-411,